Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04960579Phase 1Active Not Recruiting

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Role: lead

NCT03741127Phase 1Active Not Recruiting

Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Role: lead

NCT06014762Phase 1Recruiting

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Role: lead

NCT05239143Phase 1Active Not Recruiting

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Role: lead

NCT04249947Phase 1Terminated

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Role: lead

NCT03288493Phase 1Terminated

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Role: lead

All 6 trials loaded